Our meta‐analysis provides the most comprehensive evidence supporting the efficacy of pioglitazone as a third‐line agent in patients with T2DM inadequately controlled on metformin and SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.